Treatment of Depression with Insomnia

Primary Treatment Strategy

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the foundation of insomnia treatment, even when depression is present, due to its superior long-term efficacy compared to pharmacotherapy alone 2, 3
CBT-I should include sleep restriction therapy, limiting time in bed to match actual sleep duration, with weekly adjustments based on sleep efficiency >85-90% 4, 3
The American Academy of Sleep Medicine suggests stimulus control, using bed only for sleep and sex, and leaving the bedroom if unable to sleep within 15-20 minutes 3
Cognitive restructuring should address dysfunctional beliefs about sleep and catastrophic thinking about sleep loss 3
Sleep hygiene education should include a regular sleep-wake schedule, avoiding caffeine/alcohol/nicotine before bed, and optimizing the sleep environment 4, 1

The American Academy of Sleep Medicine recommends selecting an antidepressant with favorable sleep-promoting properties, such as mirtazapine or trazodone, rather than adding a separate hypnotic 4, 5
Mirtazapine 15-30 mg at bedtime is a preferred first-line antidepressant for depression with insomnia, blocking 5-HT2 receptors and improving sleep efficiency 4, 5
Trazodone at full antidepressant doses (150-300 mg) has 5-HT2 blocking properties and minimal anticholinergic activity, making it a suitable option for depression with insomnia 4, 5

The American Academy of Sleep Medicine recommends using short-term pharmacotherapy, such as zolpidem 10 mg or eszopiclone 2-3 mg, if CBT-I plus appropriate antidepressant selection is insufficient for insomnia control 4, 1
Low-dose doxepin 3-6 mg is a second-line option for sleep maintenance, specifically for patients who have not responded to first-line treatments 1
Suvorexant, an orexin receptor antagonist, is also a second-line option for sleep maintenance 1

The American Academy of Sleep Medicine warns against using low-dose sedating antidepressants (e.g., trazodone 50 mg, mirtazapine 7.5 mg) as monotherapy for depression, as this undertreats the depression 4, 5
The American Academy of Sleep Medicine advises against prescribing SSRIs/SNRIs without addressing their sleep-disrupting effects, and recommends using caution when prescribing hypnotics long-term without periodic reassessment and concurrent behavioral interventions 1, 2
The American Academy of Sleep Medicine recommends avoiding multiple sedating agents simultaneously, which can increase fall risk, cognitive impairment, and complex sleep behaviors 1
Special population warnings include using lower medication doses in elderly patients, avoiding benzodiazepines in patients with substance abuse history, and using caution with sleep restriction therapy in patients with bipolar disorder or seizures 4, 1, 3